Candida endophthalmitis: an unusual complication of prolonged intravenous access

M Vose, S Beatty, S J Charles

Abstract
A 16 year old boy awaiting a defunctioning colostomy for Crohn's disease complained of reduced vision in his left eye. Four weeks previously candida had been isolated from his central line used for parenteral feeds. Fundal examination of the left eye revealed a macular abscess with a classic “string of pearls” appearance of multiple vitreous abscesses. This was treated with pars plana vitrectomy and intravitreal antifungal therapy. Microbiological studies confirmed a diagnosis of candida endophthalmitis. (Postgrad Med J 2001;77:119–120)

Keywords: candida; endophthalmitis; intravitreal

Candida albicans is the most common causative agent in intraocular fungal infection. Candida endophthalmitis is typically seen in immunocompromised patients, but may also occur in association with intravenous access in the presence of a normal immune system. Examples of intravenous introduction of candida include intravenous drug users; prolonged intravenous/parenteral therapy, and anaesthetic induction agents.

Case report
A 16 year old boy was referred with decreased visual acuity and redness of the left eye. Four weeks previously he had candida species isolated from a central line used for parenteral nutrition while awaiting a defunctioning colostomy for Crohn’s disease and was started on oral fluconazole 200 mg twice a day. No other predisposing factors (immunodeficiency, corticosteroid treatment, cytotoxic chemotherapy, or prolonged systemic antibiotic treatment) were identified.

The visual acuity in the affected eye was reduced to counting fingers. Anterior segment examination was unremarkable but fundoscopy revealed a raised white abscess at the macula with vitritis and microabscesses overlying the inferior arcade (fig 1). Examination of the fellow eye was completely normal. A clinical diagnosis of candida endophthalmitis was made and he was treated with intravitreal amphotericin (10 µg) and the dose of fluconazole was increased to 400 mg orally twice daily. One week later, there was no clinical improvement and, therefore, the patient underwent a pars plana vitrectomy with vitreous sampling for microbiological studies and repeat intravitreal injection of amphotericin B (10 µg).

Microbiological investigations confirmed the presence of C albicans sensitive to fluconazole. As the patient had already been receiving the appropriate antifungal agent for one month since the contaminated central line had been removed, the dose of fluconazole was increased to 600 mg twice a day.

At six weeks the visual acuity had improved to 6/36 and on review six months later the infection had completely resolved and the patient’s visual acuity had improved to 6/9 (fig 2).

Discussion
Candida species is widespread in the hospital environment and is a commensal organism in the upper respiratory, gastrointestinal, and genitourinary tracts. Consequently, a high index of suspicion of candida endophthalmitis is required in patients with predisposing factors. Blood cultures are frequently negative. When suspected, prompt ophthalmic referral is advised as intravitreal amphotericin and oral antifungals are highly effective in eradicating the organism and preserving vision. Fluconazole (a triazole) is the oral antifungal agent of choice. The usual dose is between 200–400 mg/day in divided doses but up to 1600 mg/day may be used in severe systemic disorders.

Those patients with renal or hepatic impairment, or who are pregnant, need more careful
Learning points

1. A high index of suspicion of fungal infection is warranted in patients with the following risk factors:
   (A) Intravenous drug use
   (B) Immunodeficiency
   (C) Prolonged corticosteroid therapy
   (D) Cytotoxic chemotherapy
   (E) Prolonged systemic antibiotic treatment
   (F) Parenteral feeds

2. Early diagnosis of candida endophthalmitis improves visual prognosis

3. Physical/ophthalmic signs may be minimal either because:
   (A) Patient’s general condition may be poor: intravenous drug use, prolonged intravenous therapy (antibiotics, steroid, cytotoxic, parenteral)
   (B) Eye pathology may be very subtle. Patients may present with a slight red eye, photophobia or floaters. Visual acuity may be normal if the macula or the optic nerve are not involved

4. Early lesions may only be evident on fluorescein angiography

5. Anterior segment inflammation (iritis, scleritis, or hypopyon) is a late manifestation of posterior segment infection by candida

6. Transient side effects of empirical antimycotic therapy include: anaemia, thrombocytopenia, increased serum creatinine

7. Urgent specialist ophthalmic opinion is indicated in all cases

8. Oral fluconazole may be started when the diagnosis is suspected

9. Intravitreal antifungal agents are required in those patients with vitreous involvement

10. Early vitrectomy is indicated when the efficacy of therapy (intravenous/intravitreal) is insufficient

increments in their dosage. Vitrectomy is reserved for insufficient clinical improvement, obtaining adequate samples for sensitivity determination and to debulk lesions threatening a retinal detachment.

Candida endophthalmitis: an unusual complication of prolonged intravenous access

M Vose, S Beatty and S J Charles

Postgrad Med J 2001 77: 119-120
doi: 10.1136/pmj.77.904.119

Updated information and services can be found at: http://pmj.bmj.com/content/77/904/119

These include:

**References**
This article cites 8 articles, 1 of which you can access for free at: http://pmj.bmj.com/content/77/904/119#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Ophthalmology (101)
- Colon cancer (60)
- Drugs: infectious diseases (221)
- Gastrointestinal surgery (80)
- Inflammatory bowel disease (37)

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/